Background: lung cancer is one of the most incident neoplastic diseases and a leading cause of death for cancer worldwide. Knowledge of the incidence of druggable genetic alterations, their correlation with clinical and pathological features of the disease, and their interplay in cases of co-occurrence is crucial for selecting the best therapeutic strategies of patients with non-small cell lung cancer. In this real-life study, we describe the molecular epidemiology of genetic alterations in five driver genes and their correlations with the demographic and clinical characteristics of Sardinian patients with lung adenocarcinoma. Methods: Data from 1440 consecutive Sardinian patients with a histologically proven diagnosis of lung adenocarcinoma from January 2011 through July 2016 were prospectively investigated. EGFR mutation analysis was performed for all of them, while KRAS and BRAF mutations were searched in 1,047 cases; ALK alterations were determined with fluorescence in situ hybridization in 899 cases, and cMET amplifications in 788 cases. Results: KRAS mutations were the most common genetic alterations involving 22.1% of the cases and being mutually exclusive with the EGFR mutations, which were found in 12.6% of them. BRAF mutations, ALK rearrangements, and cMET amplifications were detected in 3.2%, 5.3%, and 2.1% of the cases, respectively. Concomitant mutations were detected only in a few cases. Conclusions: Almost all the genetic alterations studied showed a similar incidence in comparison with other Caucasian populations. Concomitant mutations were rare, and they probably have a scarce impact on the clinical management of Sardinians with lung adenocarcinoma. The low incidence of concomitant cMET amplifications at diagnosis suggests that these alterations are acquired in subsequent phases of the disease, often during treatment with TKIs.
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1,440 Sardinian patients with lung adenocarcinoma / Maria, Colombino; Paliogiannis, Panagiotis; Cossu, Antonio Giuseppe Maria; Davide Adriano Santeufemia, ; Sardinian Lung Cancer (SLC) Study Group, ; Maria Cristina Sini, ; Milena, Casula; Grazia, Palomba; Antonella, Manca; Marina, Pisano; Doneddu, Valentina; Giuseppe, Palmieri.; Palmieri, Giuseppe. - In: BMC PULMONARY MEDICINE. - ISSN 1471-2466. - 19:(2019), p. 209. [10.1186/s12890-019-0964-x]
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1,440 Sardinian patients with lung adenocarcinoma.
Panagiotis Paliogiannis
;Antonio Cossu
;Valentina Doneddu
;Palmieri, Giuseppe
2019-01-01
Abstract
Background: lung cancer is one of the most incident neoplastic diseases and a leading cause of death for cancer worldwide. Knowledge of the incidence of druggable genetic alterations, their correlation with clinical and pathological features of the disease, and their interplay in cases of co-occurrence is crucial for selecting the best therapeutic strategies of patients with non-small cell lung cancer. In this real-life study, we describe the molecular epidemiology of genetic alterations in five driver genes and their correlations with the demographic and clinical characteristics of Sardinian patients with lung adenocarcinoma. Methods: Data from 1440 consecutive Sardinian patients with a histologically proven diagnosis of lung adenocarcinoma from January 2011 through July 2016 were prospectively investigated. EGFR mutation analysis was performed for all of them, while KRAS and BRAF mutations were searched in 1,047 cases; ALK alterations were determined with fluorescence in situ hybridization in 899 cases, and cMET amplifications in 788 cases. Results: KRAS mutations were the most common genetic alterations involving 22.1% of the cases and being mutually exclusive with the EGFR mutations, which were found in 12.6% of them. BRAF mutations, ALK rearrangements, and cMET amplifications were detected in 3.2%, 5.3%, and 2.1% of the cases, respectively. Concomitant mutations were detected only in a few cases. Conclusions: Almost all the genetic alterations studied showed a similar incidence in comparison with other Caucasian populations. Concomitant mutations were rare, and they probably have a scarce impact on the clinical management of Sardinians with lung adenocarcinoma. The low incidence of concomitant cMET amplifications at diagnosis suggests that these alterations are acquired in subsequent phases of the disease, often during treatment with TKIs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.